Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.
Stanley
William C
WC
Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44122, USA. WCS4@case.edu
Sabbah
Hani N
HN
D050260:Carbohydrate Metabolism / Q000187:drug effects; D002986:Clinical Trials as Topic; D004734:Energy Metabolism / Q000187:drug effects; D005227:Fatty Acids / Q000378:metabolism*; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000378:metabolism*; D010084:Oxidation-Reduction; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D005227:Fatty Acids; D014665:Vasodilator Agents; D014292:Trimetazidine